Pardoprunox
- Generic Name
- Pardoprunox
- Drug Type
- Small Molecule
- Chemical Formula
- C12H15N3O2
- CAS Number
- 269718-84-5
- Unique Ingredient Identifier
- 5R72CHP32S
- Background
Pardoprunox has been used in trials studying the treatment of Early Stage Parkinson's Disease and Advanced Stage Parkinson's Disease. Pardoprunox is a partial dopamine D2 agonist and noradrenergic agonist with serotonin 5-HT1A agonist properties.
A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.
- Conditions
- Advanced Stage Parkinson's Disease
- Interventions
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2011-08-26
- Lead Sponsor
- Abbott Products
- Target Recruit Count
- 37
- Registration Number
- NCT00903838
- Locations
- ๐ฎ๐น
Site Reference ID/Investigator# 45435, Cassino, Italy
๐ฎ๐นSite Reference ID/Investigator# 45436, Chieti Scalo, Italy
๐ฉ๐ชSite Reference ID/Investigator# 45422, Tuebingen, Germany
An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2010-09-13
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT00407095
- Locations
- ๐บ๐ธ
S308.3.007 Site # 221, Chicago, Illinois, United States
๐ง๐ฌS308.3.007 Site # 120, Sofia, Bulgaria
๐จ๐ฑS308.3.007 Site # 141, Santiago de Chile, Chile
An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients
- First Posted Date
- 2006-06-09
- Last Posted Date
- 2009-02-06
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 202
- Registration Number
- NCT00335374
- Locations
- ๐จ๐ณ
389, Kaohsiung Hsien, Taiwan
๐จ๐ณ387, Kaohsiung, Taiwan
๐ต๐ฑ368, Leszno, Poland
An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2009-01-26
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 224
- Registration Number
- NCT00332917
- Locations
- ๐บ๐ธ
Site 281, Pittsburgh, Pennsylvania, United States
๐จ๐ฆSite 269, Saskatoon, Canada
๐ฆ๐ทSite 208, Capital Federal, CBA, Argentina
SLV308 for Treatment of Patients With Early Parkinson's Disease
- Conditions
- Early Stage Parkinson's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2008-08-29
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 468
- Registration Number
- NCT00269516
- Locations
- ๐ง๐ช
Site 100, Brussels, Belgium
๐ง๐ฌSite 107, Plovdiv, Bulgaria
๐ง๐ฌSite 104, Sofia, Bulgaria
Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease
- Conditions
- Parkinson's Disease
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2009-01-30
- Lead Sponsor
- Solvay Pharmaceuticals
- Registration Number
- NCT00134251
- Locations
- ๐ท๐ธ
Site 34, Belgrade, Serbia
๐ง๐ฌSite 14, Sofia, Bulgaria
๐ท๐ธSite 33, Nis, Serbia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.